These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25999911)

  • 1. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.
    Herbert MK; Aerts MB; Beenes M; Norgren N; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
    Front Neurol; 2015; 6():91. PubMed ID: 25999911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
    Hu X; Yang Y; Gong D
    Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers.
    Mangesius S; Mariotto S; Ferrari S; Pereverzyev S; Lerchner H; Haider L; Gizewski ER; Wenning G; Seppi K; Reindl M; Poewe W
    Parkinsonism Relat Disord; 2020 Aug; 77():57-63. PubMed ID: 32622301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders.
    Zhang P; Chen J; Cai T; He C; Li Y; Li X; Chen Z; Wang L; Zhang Y
    Front Aging Neurosci; 2022; 14():909552. PubMed ID: 35992605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes.
    Quadalti C; Calandra-Buonaura G; Baiardi S; Mastrangelo A; Rossi M; Zenesini C; Giannini G; Candelise N; Sambati L; Polischi B; Plazzi G; Capellari S; Cortelli P; Parchi P
    NPJ Parkinsons Dis; 2021 Oct; 7(1):93. PubMed ID: 34635674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease.
    Abdo WF; Bloem BR; Van Geel WJ; Esselink RA; Verbeek MM
    Neurobiol Aging; 2007 May; 28(5):742-7. PubMed ID: 16678934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.
    Herbert MK; Eeftens JM; Aerts MB; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
    Parkinsonism Relat Disord; 2014 Jan; 20(1):112-5. PubMed ID: 24075122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism.
    Constantinescu R; Rosengren L; Eriksson B; Blennow K; Axelsson M
    Acta Neurol Scand; 2019 Aug; 140(2):147-156. PubMed ID: 31070772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy.
    Tokutake T; Kasuga K; Tsukie T; Ishiguro T; Shimohata T; Onodera O; Ikeuchi T
    Parkinsonism Relat Disord; 2022 Sep; 102():30-35. PubMed ID: 35933820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
    Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
    Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
    Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
    Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies.
    Canaslan S; Schmitz M; Villar-Piqué A; Maass F; Gmitterová K; Varges D; Lingor P; Llorens F; Hermann P; Zerr I
    Front Aging Neurosci; 2021; 13():717930. PubMed ID: 34630068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
    Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls.
    Marques TM; van Rumund A; Bruinsma IB; Wessels HJCT; Gloerich J; Esselink RAJ; Bloem BR; Kuiperij HB; Verbeek MM
    Mol Neurobiol; 2019 Jul; 56(7):5067-5074. PubMed ID: 30465235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.